Clinical Trial Design—What is the Critical Question for Decision-Making?

Jingjing Ye, Hong Tian, Xiang Tony Guo and Naitee Ting ()
Additional contact information
Jingjing Ye: BeiGene
Hong Tian: BeiGene
Xiang Tony Guo: BeiGene
Naitee Ting: Boehringer-Ingelheim Pharmaceuticals, Inc

Statistics in Biosciences, 2023, vol. 15, issue 2, No 10, 475-489

Abstract: Abstract Students with statistics or biostatistics majors learned from their classes that by focusing on a single, well-defined question for a given design, the results are more likely to be informative and meaningful. This principle can be studied from many prominent statisticians including RA Fisher and J Neyman. The same principle applies in clinical trial designs. However, when designing clinical trials, statisticians often neglect this principle and make things more complicate than they should be. A poorly designed trial with too many objectives usually cannot answer any question satisfactorily. This manuscript is motivated by the Project Optimus initiative proposed by FDA Oncology Center of Excellence (OCE) 2022. Given the paradigm shift from cytotoxic drugs to target and immunotherapies, the objective is to promote the dose-finding or proof-of-concept design part of the oncology drug development closer to the designs in chronic disease drug development and incorporate patient experience into the safety and tolerability consideration. The design differences exist because of the disease; however, the fundamental principal have been the same and should still be the same. This manuscript attempts to clarify this confusion, with an emphasis on Phase II clinical trials.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s12561-023-09365-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:stabio:v:15:y:2023:i:2:d:10.1007_s12561-023-09365-x

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/12561

DOI: 10.1007/s12561-023-09365-x

Access Statistics for this article

Statistics in Biosciences is currently edited by Hongyu Zhao and Xihong Lin

More articles in Statistics in Biosciences from Springer, International Chinese Statistical Association
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().